MARLBOROUGH, Mass.--(BUSINESS WIRE)--Cytyc Corporation (Nasdaq: CYTC), a leading provider of surgical and diagnostic products targeting cancer diagnostics and women’s health, today announced that twelve studies presenting data on the MammoSite® Radiation Therapy System (RTS) were featured at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Philadelphia. The studies evaluated a range of parameters including insertion techniques, treatment efficacy, toxicity rates, and cosmetic results. The studies presented included single institutional experiences as well as multi-site evaluations. Among the data presented were:
